Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)
Opportunity Score
Confidence: 50%
Complexity: low
717 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
Non-exclusive discount agreements for finished medicinal products (Aflibercept 40mg and Ranibizumab) under German SGB V using an Open-House model. Pharmaceutical companies can join anytime under uniform conditions. The notice is not a public procurement under EU directives.
Strengths
Documents available
Open procedure
Low complexity
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- Must be a pharmaceutical company or consortium
- Request participation documents from AOK Hessen
- Submit completed, stamped, and signed original documents
Buyer
Name
AOK - Die Gesundheitskasse in Hessen Postanschrift: Kölner Str. 8, 65760 Eschborn Land: Deutschland Kontaktstelle(n): z. Hd. Frau Corinna Varelmann E-Mail: [email protected] Telefon: +49 69 6681 6259 711 Internet-Adresse(n):Hauptadresse: http://www.aok.de/hessen/
Location
Eschborn, DEU
Identifier
DE114110216
Lots (2)
Discount agreement for Aflibercept 40mg. All qualified pharmaceutical companies can join at any time. No exclusivity.
Discount agreement for Ranibizumab. All qualified pharmaceutical companies can join at any time. No exclusivity.
Procurement Details
Publication
14 Jun 2026
Deadline
01 Jun 2028, 10:00
Procedure
open
Contract
supplies
Language
DEU
Publication #
408239-2026
Classification
Documents (1)
Opportunity Score
Confidence: 50%
Complexity: low
717 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation